A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation

The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS patients with SF3B1 mutation in Zhejiang province of China....

Full description

Bibliographic Details
Main Authors: Liya Ma, Bin Liang, Huixian Hu, Wenli Yang, Shengyun Lin, Lihong Cao, Kongfei Li, Yuemin Kuang, Lihong Shou, Weimei Jin, Jianping Lan, Xingnong Ye, Jing Le, Huyi Lei, Jiaping Fu, Ying Lin, Wenhua Jiang, Zhiying Zheng, Songfu Jiang, Lijuan Fu, Chuanyong Su, XiuFeng Yin, Lixia Liu, Jiayue Qin, Jie Jin, Shenxian Qian, Guifang Ouyang, Hongyan Tong
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
Myelodysplastic syndrome (MDS)
SF3B1 mutation
RUNX1
EZH2
Ras
prognostic scoring model
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.905490/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.905490/full

Similar Items